comparemela.com

Latest Breaking News On - Secarna pharmaceuticals - Page 1 : comparemela.com

Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Discover and Develop Peptide-conjugated Targeted Antisense Oligonucleotide Therapeutics

Partnership expands spectrum of Secarna's capabilities for the development of targeted ASOs beyond antibodies and sugar molecules New platform capabilities extend the reach of Secarna's antisense

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conj

EQS-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): AgreementSecarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics 28.05.2024 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announ.

EQS-News: Secarna Pharmaceuticals GmbH & Co KG: Secarna Pharmaceuticals presents data at SITC demonstrating the potential of antisense oligonucleotides in targeting NRP1

EQS-News: Secarna Pharmaceuticals GmbH & Co KG: Secarna Pharmaceuticals presents data at SITC demonstrating the potential of antisense oligonucleotides in targeting NRP1
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Secarna Pharmaceuticals Presents Data at SITC Demonstrating the Potential of Antisense Oligonucleotides in Targeting NRP1

Secarna Pharmaceuticals Presents Data at SITC Demonstrating the Potential of Antisense Oligonucleotides in Targeting NRP1
nashvilleherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nashvilleherald.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.